
Boundless Life · 24 Sept 2026 · 1 h 05 min
PT-141 and the melanocortin system
Listen on SpotifyOur summary
An overview of bremelanotide (PT-141), how it acts on melanocortin receptors in the brain, and what its clinical trials measured.
Key points
- PT-141 works centrally, not on blood flow
- Phase 3 trials led to FDA approval for one indication
- Nausea was the most reported side effect in trials
Exclusive for PeptideNews readers
Get exclusive access to a trusted source of RUO peptides
As a research site, we can give you access to a supplier that meets the standards we write about.
- 60-day money-back guarantee
- Temperature-protected shipping
- Produced in the EU
- Third-party lab tested
- Traceable testing
- 99% purity
- Delivery in 2–5 days across the EU
For research use only (RUO). Not for human consumption.